IL-17 not only further exacerbates the pathological changes in MG by promoting the expression of inflammatory cytokines and inflammatory responses at neuromuscular junctions (15–18), but also disrupts immune tolerance by affecting the function of regulatory T cells (Treg), leading to the immune system’s attack on self-antigens (19). This evidence concerns the gene IL17A and myasthenia gravis.